ÜBER DIESE EPISODE
Health AI Investing: Scientia Ventures • Harry Glorikian
Artificial intelligence is beginning to reshape healthcare, drug discovery, diagnostics, and even the structure of business itself.
In this episode of UnNatural Selection, Nic Encina sits down with Harry Glorikian — General Partner at Scientia Ventures and Research Affiliate at the MIT Media Lab — to explore the collision between AI, biology, venture capital, and the future of innovation.
Together, they discuss how investors distinguish genuine technological breakthroughs from hype, why data infrastructure and inferencing may become the next great competitive battlegrounds, and how startups are increasingly challenging legacy healthcare and pharmaceutical systems.
The conversation dives into the evolution from traditional AI to large language models, the future of drug discovery, clinical trials, intelligent agents, digital health ecosystems, and why companies that fail to adapt to accelerating technological change may suddenly find themselves obsolete.
From healthcare transformation to societal evolution in the age of AI, this episode explores what happens when innovation itself begins compounding faster than humans can comfortably track.
